Crispr News
-
Intellia Therapeutics: A Leader in CRISPR/Cas9 Genome Editing ... - Best StocksApril 2, 2023
-
CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni ... - MarketBeatApril 1, 2023
-
Here's a New Million-Dollar Reason to Buy CRISPR Therapeutics - The Motley FoolApril 1, 2023
-
Pediatric Cancer Cell Atlas Uncovers Clues About Cancer Drivers ... - GenomeWebMarch 31, 2023
-
Cutting With CRISPR: Assessing Safety as Technology Moves Into ... - Technology NetworksMarch 31, 2023
-
Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce ... - Cancer DiscoveryMarch 31, 2023
-
Scribe Therapeutics to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days - Yahoo FinanceMarch 31, 2023
-
This Top Growth Stock Is Targeting a Multi-Billion-Dollar Market ... - NasdaqMarch 31, 2023
-
Genome-wide tiled detection of circulating Mycobacterium ... - Nature.comMarch 31, 2023
-
5 Bargain-Basement Stocks to Buy Right Now - NasdaqMarch 31, 2023
-
Buy Crispr Therapeutics On Approval Odds (NASDAQ:CRSP) - Seeking AlphaMarch 31, 2023
-
Opportunity in the CRISPR Gene Editing Market | High Market ... - MedgadgetMarch 31, 2023
-
CRISPR cats and dogs? Royal Society for the Prevention of Cruelty ... - Genetic Literacy ProjectMarch 31, 2023
-
CRISPR pioneer Jennifer Doudna to speak April 4 in Chicago - Northwestern NowMarch 31, 2023
-
Brassinosteroid gene regulatory networks at cellular resolution in ... - ScienceMarch 30, 2023
-
CRISPR editing in the lung with novel lipids - Nature.comMarch 30, 2023
-
Nucleotide metabolism regulates human telomere length via ... - Nature.comMarch 30, 2023
-
One-Time Treatment: Base Editing Shows Promise vs. SMA - Genetic Engineering & Biotechnology NewsMarch 30, 2023
-
2 Reasons to Sell Editas Medicine Stock and 1 Reason to Buy It - NasdaqMarch 30, 2023
-
Editing the cell's transcripts - Drug Discovery NewsMarch 30, 2023

Nobel Prize winning CRISPR biochemist Jennifer Doudna and noted author Walter Isaacson discuss her work and his profile of her. The new book is titled “The Code Breaker,” release date March 9, 2021. CBS Sunday Morning, March 7, 2021
CRISPR-Cas9 vs. Cancer – A system to successfully pinpoint and destroy metastatic brain and ovarian cancer cells in mice has been reported by Tel Aviv University Researchers in the journal Science Advances. Tel Aviv University video. November 16, 2020
Tel Aviv University cancer researcher Dr. Dan Peer speaks with journalist Maria Menounos about efforts to treat glioblastoma and ovarian cancer in mice using CRISPR-Cas9 to target and kill cancer cells. BETTER TOGETHER video. December 29, 2020
DOUDNA, CHARPENTIER WIN NOBEL PRIZE IN CHEMISTRY FOR CRISPR Cas9 DEVELOPMENT.October 7, 2020
Reaction From Dr. Emmanuelle Charpentier Obtained by CRISPRInsider: “Please know that I am thrilled with this amazing news. I am truly honored to have been chosen as a recipient of this most prestigious award and herewith join the very distinguished group of former laureates.”
Crispr Insider reports on and helps ignite the DNA revolution currently underway.--This revolution to engineer DNA is transforming human life in ways unimaginable since Watson and Crick discovered DNA in 1953.

CRISPR Cas9 v. Banana Blight – Can genes in the world’s most popular variety of banana be edited to fight a fungus threatening the global supply? Tropic Biosciences CEO Gilad Gershon answers questions from CRISPRInsider’s Bob Males. London, August 7, 2020
"Anything we can dream of in terms of biology and chemistry we can probably achieve through molecular technologies like editing."
Dr. George Church, Professor at MIT & Harvard. Topic: The man of the future will quite likely be unrecogizable to current humans in 250 years.
Boston, June 5, 2018
Part 1 – Dr. George Church, Professor at MIT & Harvard. Topics: how the Human Genome Project led to CRISPR gene editing; consumer uses of genetic information; immunotherapy. Boston, June 5, 2018
Part 2 – Dr. George Church, Professor at Harvard & MIT. Topics: Can CRISPR gene editing reinvent man?; most desireable genes; unintended consequences; treating cancer; CRISPR preps pigs for transplantation. Boston, June 5, 2018
Part 3 – Dr. George Church. Topics: FDA hold on CRISPR clinical trial; sickle cell & thalassemia. Boston, June 5, 2018
Part 4 – Dr. George Church: CRISPR “very exciting for plant and animal agriculture.” Boston, June 5, 2018
Part 5 – Dr. George Church: Monitor the spread of synthetic biology: “There should be licensing and surveillance.” Boston, June 5, 2018
Part 6 – Dr. George Church
Dr. Feng Zhang discusses his work at CRISPRcon18. Boston, June 4, 2018
Dr. Duanqing Pei, Chinese Academy of Sciences: Why Chinese CRISPR research is focusing on Beta Thalassemia and Sickle Cell Diseases. Boston, June 5, 2018
Dr. Duanqing Pei, Chinese Academy of Sciences: Clinical trials guidelines and principles “closely related” in U.S. and China. Boston, June 5, 2018
Pat 1, Mice Against Ticks. Can CRISPR gene editing wipe out Lyme Disease? Carrie Fyler, PhD, comments. Boston, June 5, 2018. 2:34.
Part 2, Mice Against Ticks. A Massachusetts biology teacher offers a possible timeline for a test plan to eradicate Lyme Disease on Martha’s Vineyard and Nantucket Islands. Boston, June 5, 2018. 4:11
Part 3, Mice Against Ticks. How the public has responded, so far, to the Mice Against Ticks gene editing proposal. Boston, June 5, 2018. :43
Mice Against Ticks, Part 4. How Lyme Disease could get stopped on Martha’s Vineyard and Nantucket Islands using the gene editing tool CRISPR CAS9 on field mice to reduce the incidence of this tick-borne disease. Boston, June 5, 2018. :51
Dr. Tom Barnes, Intellia Therapeutics: Why recent CRISPR CAS9/Cancer headlines are “unwarranted.” NYC, June 21, 2018
Dr. Tom Barnes, Intellia Therapeutics, assesses the CRISPR clinical push in China. NYC, June 21, 2018. 1:45
Dr. Tom Barnes, Intellia Therapeutics: FDA’s hold on CTX0001 “might be nothing.” NYC, June 21, 2018. :47
Dr. Tom Barnes, Intellia Therapeutics, addresses the cost complexities of personalized medicine. NYC, June 21, 2018
Dr. Tom Barnes, Intellia Therapeutics, discusses newest CRISPR Cas9 U.S. patent for Doudna and Charpentier. NYC, June 21, 2018
Dr. Tom Barnes, Intellia Therapeutics: The areas we’re’ working on with CRISPR. NYC, June 21, 2018
CRISPR News from China
Russia registered a new crown of the vaccine was the top magazine critics questioned;China’s first HIV pre-exposure prophylaxis drug approved
August 14, 2020West Media:scientists are trying to be“genetic scissors”for the fight against the new Crown virus _ the message…
August 12, 2020West Media:scientists are trying to be“genetic scissors”for the fight against the new Crown virus
August 11, 2020Scientists in the development of early use of CRISPR knock-out genetic information
August 10, 2020“Gene writing”can be broken CRISPR limitations? This cutting-edge, or the rewriting of genetic disease in the future
August 10, 2020From today 185 billion USD m & a,see the health events to the medical health industry opportunities
August 6, 2020CRISPR-base editor“Nova”ABE8e exactly how the ratio of early ABEs fast 1100 times?
August 6, 2020Anhui Wanjia hotline:secondary view WAN West Pharmaceutical flood relief in action
August 5, 2020Science heavy! The CRISPR field two“gurus”cooperation in depth analysis of single base editor…
August 4, 2020With CRISPR diagnosis of the underlying methodology of an exclusive patent,Tolo creatures won million strategic financing
August 4, 2020Focus on CRISPR diagnostic techniques,Tolo creatures won tens of millions of dollars financing
August 4, 2020Nat Metab | genome-wide CRISPR screening found that type I diabetes new therapeutic targets—RNLS
August 3, 20202020 7 on CRISPR/Cas the latest research progress
July 30, 2020Researchers at the largest of the CRISPR system in the positioning mechanism
July 30, 2020From R & D to filings,gold, Rui for CRISPR applications in Cell Therapy provides one-stop new programme
July 29, 2020
Contact
- Nothing to display ...